Citations

Clear

3030 citation(s) found for "Susan, M".

Further Defining the Role of the Laboratory Genetic Counselor
Waltman, Lindsey, Runke, Cassandra , Balcom, Jessica R. , Riley, Jacquelyn D. , Lilley, Margaret , Christian, Susan , Zetzsche, Lindsay H., Goodenberger, McKinsey L. , Balcom, Jessica, Zetzsche, Lindsay, Goodenberger, McKinsey

Mayo Clinic

Journal of Genetic Counseling | February 20, 2016 | Volume: 25 | Issue: 4 | Pages: 786-798

10.1007/s10897-015-9927-4 | PMID 26895873 Get It

AbstractLaboratory genetic counseling is becoming increasingly common as a result of increased laboratory services and genetic testing menus, as well as growing job responsibilities. Christian et al. (2012) provided the first quantitative data regarding the roles of the laboratory‐based genetic counselor (LBGC) finding that two of the most prevalent roles are as customer liaisons and communicators of test results. The goal of the present study was to further delineate the role of the LBGC by addressing specific tasks that LBGCs are involved with on a day‐to‐day basis. A survey was designed to expand upon themes identified in the Christian et al. (2012) study by querying specific tasks performed in several categories of potential LBGC job duties. An invitation for LBGCs to participate was distributed via email to the membership of the National Society of Genetic Counselors (NSGC) and the Canadian Association of Genetic Counsellors (CAGC). We identified 121 genetic counselors who primarily work in the laboratory setting or whose job role includes a laboratory component. Almost all respondents performed customer liaison/case coordination (95 %), and interpretation and result reporting (88 %). The most frequently performed tasks within these categories involved addressing questions from clients, making phone calls with genetic testing results, obtaining clinical or family history information for results interpretation, and composing case‐specific interpretations for unique results and/or obtaining literature references to support interpretations. The study results also point to trends of expanding roles in sales and marketing, variant interpretation and management responsibilities. Results of this study may be useful to further define the full scope of practice of LBGCs, aid in the development of new LBGC positions and expand current positions to include roles related to test development, research, and student supervision. It may also aid in curriculum updates for training programs to increase exposure to LBGC roles.
Predictors of incipient dysfunction of all cardiac chambers after treatment of metastatic renal cell carcinoma by tyrosine kinase inhibitors
Moustafa, Sherif, Ho, Thai H. , Shah, Parth , Murphy, Katie , Nelluri, B.K., Lee, Howard , Wilansky, Susan , Mookadam, Farouk , Nelluri, Bhargava K, Ho, Thai

Mayo Clinic

Journal of Clinical Ultrasound | February 15, 2016 | Volume: 44 | Issue: 4 | Pages: 221-230

10.1002/jcu.22333 | PMID 26875513 Get It

ABSTRACTPurposeWe aimed to explore the hypothesis that early subclinical cardiac chamber dysfunction secondary to tyrosine kinase inhibitors (TKIs) in patients with metastatic renal cell carcinoma could be signaled by abnormal cardiac mechanics demonstrated by velocity vector imaging.MethodsEchocardiographic images were acquired from the apical views in 23 metastatic renal cell carcinoma patients. All patients had baseline and at least a 3‐month follow‐up echocardiogram after receiving TKI therapy. Subendocardial borders of all the cardiac chambers were traced to obtain volumetric and deformation indices.ResultsMean age was 67 ± 9 years with 92% men. The right ventricle peak systolic global longitudinal strain (GLɛ) and strain rate were significantly lower after TKIs (−23.49 ± 5.1 versus −19.81 ± 5.5, p = 0.002 and −1.52 ± 0.52 versus −1.24 ± 0.35 p = 0.02, respectively). LV GLɛ was not statistically different. Volumetric and deformation indices showed a minimal decrease of the right atrium reservoir and conduit functions, and no significant changes of left atrial function.ConclusionsThe right heart exhibited greater strain changes than the left heart after TKI treatment. The implications of these findings and their potential significance warrant further work. © 2016 Wiley Periodicals, Inc. J Clin Ultrasound 44:221–230, 2016
Novel Percutaneous Epicardial Autonomic Modulation in the Canine for Atrial Fibrillation: Results of an Efficacy and Safety Study
Madhavan, Malini , Venkatachalam, K, Swale, M., Gard, Joseph J., Johnson, Susan B., Suddendorf, Scott H., Mikell, Susan B. , Ladewig, Dorothy J., NOSBUSH, TONI GRABINGER, Danielsen, Andrew J., Knudson, Mark B., Asirvatham, Samuel J. , Knudson, Mark, DeSimone, Christopher V. , Asirvatham, Samuel J

Mayo Clinic

Pacing and Clinical Electrophysiology | February 8, 2016 | Volume: 39 | Issue: 5 | Pages: 407-417

10.1111/pace.12824 | PMID 26854009 Get It

BackgroundEndocardial ablation of atrial ganglionated plexi (GP) has been described for treatment of atrial fibrillation (AF). Our objective in this study was to develop percutaneous epicardial GP ablation in a canine model using novel energy sources and catheters.MethodsPhase 1: The efficacy of several modalities to ablate the GP was tested in an open chest canine model (n = 10). Phase 2: Percutaneous epicardial ablation of GP was done in six dogs using the most efficacious modality identified in phase 1 using two novel catheters.ResultsPhase 1: Direct current (DC) in varying doses (blocking [7–12 μA], electroporation [300–500 μA], ablation [3,000–7,500 μA]), radiofrequency ablation (25–50 W), ultrasound (1.5 MHz), and alcohol (2–5 mL) injection were successful at 0/8, 4/12, 5/7, 3/8, 1/5, and 5/7 GP sites. DC (500–5,000 μA) along with alcohol irrigation was tested in phase 2. Phase 2: Percutaneous epicardial ablation of the right atrium, oblique sinus, vein of Marshall, and transverse sinus GP was successful in 5/6 dogs. One dog died of ventricular fibrillation during DC ablation at 5,000 μA. Programmed stimulation induced AF in six dogs, preablation and no atrial arrhythmia in three, flutter in one, and AF in one postablation. Heart rate, blood pressure, effective atrial refractory period, and local atrial electrogram amplitude did not change significantly postablation. Microscopic examination showed elimination of GP, and minimal injury to atrial myocardium.ConclusionPercutaneous epicardial ablation of GP using DC and novel catheters is safe and feasible and may be used as an adjunct to pulmonary vein isolation in the treatment of AF in order to minimize additional atrial myocardial ablation.
Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study
Amirian, E. Susan , Zhou, Renke, Wrensch, Margaret , Olson, Sara H. , Scheurer, Michael E. , Armstrong, Georgina , McCoy, Lucie , Lau, Ching C., Claus, Elizabeth B. , Barnholtz‐Sloan, Jill S. , Schildkraut, Joellen M. , Ali‐Osman, Francis, Sadetzki, Siegal , Johansen, Christoffer , Houlston, Richard S. , Jenkins, Robert B. , Bernstein, Jonine L. , Merrell, Ryan , Davis, Faith G., Lai, Rose , Shete, Sanjay , Melin, Beatrice , Bondy, Melissa L. , Lachance, Daniel, Il’yasova, Dora , Lachance, Daniel Honore , Armstrong, Georgina , Amos, Christopher I. , Houlston, Richard S , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 5, 2016 | Volume: 25 | Issue: 2 | Pages: 282-290

10.1158/1055-9965.epi-15-0847 | PMID 26908595 Get It

Abstract Background: Several previous studies have found inverse associations between glioma susceptibility and a history of allergies or other atopic conditions. Some evidence indicates that respiratory allergies are likely to be particularly relevant with regard to glioma risk. Using data from the Glioma International Case-Control Study (GICC), we examined the effects of respiratory allergies and other atopic conditions on glioma risk. Methods: The GICC contains detailed information on history of atopic conditions for 4,533 cases and 4,171 controls, recruited from 14 study sites across five countries. Using two-stage random-effects restricted maximum likelihood modeling to calculate meta-analysis ORs, we examined the associations between glioma and allergy status, respiratory allergy status, asthma, and eczema. Results: Having a history of respiratory allergies was associated with an approximately 30% lower glioma risk, compared with not having respiratory allergies (mOR, 0.72; 95% confidence interval, 0.58–0.90). This association was similar when restricting to high-grade glioma cases. Asthma and eczema were also significantly protective against glioma. Conclusion: A substantial amount of data on the inverse association between atopic conditions and glioma has accumulated, and findings from the GICC study further strengthen the existing evidence that the relationship between atopy and glioma is unlikely to be coincidental. Impact: As the literature approaches a consensus on the impact of allergies in glioma risk, future research can begin to shift focus to what the underlying biologic mechanism behind this association may be, which could, in turn, yield new opportunities for immunotherapy or cancer prevention. Cancer Epidemiol Biomarkers Prev; 25(2); 282–90. ©2016 AACR.
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Hoff, Daniel D. Von , Mita, Monica , Ramanathan, Ramesh K., Mita, Alain C. , LoRusso, Patricia , Burris, Howard A. , Hart, Lowell L., Low, Susan C. , Parsons, Donald M., Zale, Stephen E., Summa, Jason M., Youssoufian, Hagop , Sachdev, Jasgit C. , Weiss, Glen J.

Mayo Clinic

Clinical Cancer Research | February 4, 2016 | Volume: 22 | Issue: 13 | Pages: 3157-3163

10.1158/1078-0432.ccr-15-2548 | PMID 26847057 Get It

Abstract Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen (PSMA)–targeted nanoparticle, containing docetaxel. Experimental Design: Patients with advanced solid tumors received BIND-014 every three weeks (n = 28) or weekly (n = 27), with dose levels ranging from 3.5 to 75 mg/m2 and 15 to 45 mg/m2, respectively. Results: BIND-014 was generally well tolerated, with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of the 52 patients evaluable for response, one had a complete response (cervical cancer on the every three week schedule) and five had partial responses (ampullary adenocarcinoma, non–small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and -undetectable tumors. Conclusions: BIND-014 was generally well tolerated, with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase II dose of BIND-014 is 60 mg/m2 every three weeks or 40 mg/m2 weekly. Clin Cancer Res; 22(13); 3157–63. ©2016 AACR.
American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine
Kattan, Michael W. , Hess, Kenneth R. , Amin, Mahul B. , Lü, Ying , Moons, Karl G.M., Gershenwald, Jeffrey E. , Gimotty, Phyllis A. , Guinney, Justin , Halabi, Susan , Lazar, Alexander J. , Mahar, Alyson , Weiser, Martin R. , Compton, Carolyn C. , Core, members of the AJCC Precision Medicine, Compton, Carolyn, Patel, Tushar P , Sargent, Daniel J. , Core, members of the AJCC Precision Medicine, Mahar, Alyson L , Lazar, Alexander J , Halabi, Susan , Lu, Ying , Kattan, Michael W

Mayo Clinic

CA: A Cancer Journal for Clinicians | January 19, 2016 | Volume: 66 | Issue: 5 | Pages: 370-374

10.3322/caac.21339 | PMID 26784705 Get It

The American Joint Committee on Cancer (AJCC) has increasingly recognized the need for more personalized probabilistic predictions than those delivered by ordinal staging systems, particularly through the use of accurate risk models or calculators. However, judging the quality and acceptability of a risk model is complex. The AJCC Precision Medicine Core conducted a 2‐day meeting to discuss characteristics necessary for a quality risk model in cancer patients. More specifically, the committee established inclusion and exclusion criteria necessary for a risk model to potentially be endorsed by the AJCC. This committee reviewed and discussed relevant literature before creating a checklist unique to this need of AJCC risk model endorsement. The committee identified 13 inclusion and 3 exclusion criteria for AJCC risk model endorsement in cancer. The emphasis centered on performance metrics, implementation clarity, and clinical relevance. The facilitation of personalized probabilistic predictions for cancer patients holds tremendous promise, and these criteria will hopefully greatly accelerate this process. Moreover, these criteria might be useful for a general audience when trying to judge the potential applicability of a published risk model in any clinical domain. CA Cancer J Clin 2016;66:370–374. © 2016 American Cancer Society.
AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth
Hu, Brian , Fairey, Adrian, Madhav, Anisha, Yang, Dongyun , Li, Meng , Groshen, Susan , Stephens, Craig, Kim, Philip H., Virk, Navneet, Martin, Sue Ellen , Erho, Nicholas , Jenkins, Robert B., Den, Robert B. , Xu, Tong , Xu, Yucheng, Gill, Inderbir S. , Goldkorn, Amir , Wang, Lina , Davicioni, Elai , Quinn, David I , Den, Robert B , Gill, Inderbir S

Mayo Clinic

The Prostate | January 16, 2016 | Volume: 76 | Issue: 6 | Pages: 597-608

10.1002/pros.23151 | PMID 26771938 Get It

Effect of Left Atrial Ablation Process and Strategy on Microemboli Formation During Irrigated Radiofrequency Catheter Ablation in an In Vivo Model
Takami, Mitsuru , Parker, Kay D., Welker, Kirk M. , Johnson, Susan B., Packer, Douglas L. , Lehmann, H. Immo

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | January 14, 2016 | Volume: 9 | Issue: 1 | Pages: No page available

10.1161/circep.115.003226 | PMID 26763224 Get It

Background— Formation of microemboli during catheter ablation has been suggested as a cause for asymptomatic cerebral emboli. However, it is unknown which part of the process and ablation setting/strategy is most strongly related to this occurrence. Methods and Results— A total of 27 pigs were used. Catheter/sheath manipulations in left atrium were performed in 25 of 27 pigs outfitted with microemboli monitoring systems. Ablations using open-irrigated radiofrequency catheters were performed in 18 of 25 pigs. Two of 27 pigs did not undergo left atrial procedures and were injected with microembolic materials in the carotid artery to serve as positive controls. In total, 334 sheath/catheter manipulations (transseptal puncture, sheath flushing, catheter insertion, pulmonary vein venography, and sheath exchange) and 333 radiofrequency applications (power setting, 30/50 W; point-by-point/drag ablations) were analyzed. High microbubble volume in the extracorporeal circulation loop and a high number of microembolic signals in carotid artery were observed during sheath/catheter manipulations especially in saline/contrast injections at fast speed and ablations with steam pop. Fast sheath flushing produced significantly higher microbubble volume than slow sheath flushing (median, 12 200 versus 121 nL; P <0.0001). A total of 44 of 126 (35%) blood filters in the circulation loop showed microparticles (thrombus/coagulum and tissue). Most of them were seen after radiofrequency application especially in 50-W ablations, drag ablations, and steam pop. Brain magnetic resonance imaging showed positive-embolic lesions in control pigs. Conclusions— Formation of microbubbles was the greatest during fast saline/contrast injections and steam pops, whereas high-power radiofrequency applications, drag ablations, and steam pops produced most of the microparticles.
Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer
Winham, Stacey J. , Pirie, Ailith, Chen, Y. Ann , Fogarty, Zachary C. , Earp, Madalene A. , Goodman, Marc T. , Levine, Douglas A. , Menon, Usha , Ness, Roberta B., Pearce, Celeste Leigh, Rossing, Mary Anne, Wentzensen, Nicolas , Bean, Yukie T., Bisogna, Maria, Brinton, Louise A. , Carney, Michael E. , Cunningham, Julie M. , DeFazio, Anna , Dicks, Ed , Edwards, Robert P., Gayther, Simon A. , Gore, Martin, Iversen, Edwin S., Jensen, Allan , Johnatty, Sharon E., Lester, Jenny, Lin, Hui‐Yi , Lissowska, Jolanta , Lubiński, Jan , Menkiszak, Janusz , Moysich, Kirsten B. , Pike, Malcolm C. , Ramus, Susan J. , Song, Honglin , Terry, Kathryn L. , Thompson, Pamela J., Berg, David J. van den , Vierkant, Robert A. , Vitonis, Allison F., Walsh, Christine M. , Wu, Anna H. , Group, Georgia Chenevix-Trench on behalf of Australian Ovarian Cancer Study, Schildkraut, Joellen M. , Permuth‐Wey, Jennifer, Phelan, Catherine M., Sellers, Thomas A. , Goode, Ellen L. , Webb, Penelope M. , Whiteman, David C. , Chenevix‐Trench, Georgia , Bowtell, David D.L. , Ewing, Ailith , Fazio, Anna de , Larson, Melissa C. , Anton‐Culver, Hoda , Bandera, Elisa V. , Cramer, Daniel W. , Doherty, Jennifer A. , Gronwald, Jacek , Karlan, Beth Y. , Kjær, Susanne K. , Pejovic, Tanja B. , Cybulski, Cezary , Gentry‐Maharaj, Aleksandra , Modugno, Francesmary , Orlow, Irene , Tyrer, Jonathan P. , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Berchuck, Andrew , Group, Georgia Chenevix-Trench on behalf of Australian Ovarian Cancer Study, Pharoah, Paul D.P. , Fridley, Brooke L. , Winham, Stacey J , Ramus, Susan J , Webb, Penelope M , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , Menkiszak, Janusz , Lin, Hui-Yi , Fogarty, Zachary C , Ewing, Ailith , Chenevix-Trench, Georgia , Whiteman, David C , Bowtell, David D , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 8, 2016 | Volume: 25 | Issue: 3 | Pages: 446-454

10.1158/1055-9965.epi-15-0240 | PMID 26747452 Get It

Abstract Background: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding variants may be associated with overall EOC survival and assessed their contribution in two exome-based genotyping projects of the Ovarian Cancer Association Consortium (OCAC). Methods: The primary patient set (Set 1) included 14 independent EOC studies (4,293 patients) and 227,892 variants, and a secondary patient set (Set 2) included six additional EOC studies (1,744 patients) and 114,620 variants. Because power to detect rare variants individually is reduced, gene-level tests were conducted. Sets were analyzed separately at individual variants and by gene, and then combined with meta-analyses (73,203 variants and 13,163 genes overlapped). Results: No individual variant reached genome-wide statistical significance. A SNP previously implicated to be associated with EOC risk and, to a lesser extent, survival, rs8170, showed the strongest evidence of association with survival and similar effect size estimates across sets (Pmeta = 1.1E−6, HRSet1 = 1.17, HRSet2 = 1.14). Rare variants in ATG2B, an autophagy gene important for apoptosis, were significantly associated with survival after multiple testing correction (Pmeta = 1.1E−6; Pcorrected = 0.01). Conclusions: Common variant rs8170 and rare variants in ATG2B may be associated with EOC overall survival, although further study is needed. Impact: This study represents the first exome-wide association study of EOC survival to include rare variant analyses, and suggests that complementary single variant and gene-level analyses in large studies are needed to identify rare variants that warrant follow-up study. Cancer Epidemiol Biomarkers Prev; 25(3); 446–54. ©2016 AACR.